Biomx INC 8-K filings

BiomX Inc. announced significant leadership changes, including the appointment of Michael Oster as CEO and Amir Shalom as a new director, following the resignations of Jonathan Solomon and Dr. Russell Greig.

BiomX Inc. announced the resignation of Alan Moses from its Board of Directors and the appointment of Guy Arieli and Shaked Ran as new independent directors.

BiomX Inc. announced the resignations of two directors and the appointment of Liat Bidas to its Board of Directors.

BiomX Inc. deconsolidates its wholly-owned Israeli subsidiary, BiomX Ltd., following the commencement of insolvency proceedings and the termination of key officers.

BiomX Inc. announced the consummation of a previously disclosed private placement, the appointment of Reuven Yeganeh to its Board of Directors, and the filing of a Certificate of Designations for Series Y Convertible Preferred Stock.

BiomX Inc. announced the termination of a material lease agreement for its subsidiary Adaptive Phage Therapeutics, settling all outstanding obligations with a one-time payment and a letter of credit draw.

BiomX Inc. announced a $3 million private placement of Series Y Convertible Preferred Stock and warrants, granting the investor a board seat and future participation rights.

BiomX Inc.'s Israeli subsidiary, BiomX Ltd., has filed for insolvency following the discontinuation of its Phase 2b study due to resource limitations.

BiomX Inc. announced the discontinuation of its Phase 2b clinical trial for BX004 in Cystic Fibrosis due to resource constraints, leading to significant workforce reductions and a strategic shift.

BiomX Inc. provided an update on its Phase 2b Cystic Fibrosis study, noting an ongoing FDA clinical hold due to a third-party nebulizer and a Data Monitoring Committee recommendation for an adjusted dosing regimen, pushing topline results to Q2 2026.

BiomX Inc. will implement a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025, to boost its per-share price.

BiomX announced its third quarter 2025 financial results, highlighted by positive FDA feedback for BX011 and anticipated feedback on the BX004 clinical hold.

BiomX Inc. stockholders approved the election of three Class II directors, authorized a reverse stock split, and ratified their independent accounting firm at the 2025 Annual Meeting.

BiomX Inc. announced the FDA's clinical hold on its BX004 Phase 2b study for Cystic Fibrosis is now limited to nebulizer device questions, with no concerns about the drug product, and topline results remain expected in Q1 2026.

BiomX Inc. announced a clinical hold by the FDA on its Phase 2b study for BX004 in Cystic Fibrosis due to a third-party nebulizer review, pausing U.S. enrollment while European operations continue.

BiomX announced positive Phase 2 results for BX211 in diabetic foot osteomyelitis and commenced Phase 2b dosing for BX004 in Cystic Fibrosis, alongside its second quarter 2025 financial results.

BiomX Inc. has announced the date for its 2025 Annual Meeting of Stockholders as October 16, 2025, and set the deadline for shareholder proposals for inclusion in its proxy statement.

BiomX Inc. announced the publication of new efficacy data from its Phase 1b/2a trial of BX004 in Nature Communications, demonstrating significant bacterial reduction and a strong safety profile for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.

BiomX Inc. announced positive Phase 2 clinical trial results for its lead phage therapy candidates, BX211 and BX004, demonstrating significant efficacy against antibiotic-resistant bacterial infections in diabetic foot osteomyelitis and cystic fibrosis patients, respectively.

BiomX reports positive Phase 2 trial results for BX211 in diabetic foot osteomyelitis and anticipates Phase 2b results for BX004 in cystic fibrosis in Q1 2026.

BiomX Inc. stockholders approved the exercise of certain warrants and a proposal for adjournment at a special meeting held on April 21, 2025.

BiomX reports successful Phase 2 trial results for BX211, a phage therapy targeting Diabetic Foot Osteomyelitis, showing statistically significant ulcer reduction and safety.

BiomX reports financial results for Q4 and full year 2024, providing updates on BX211 and BX004 clinical programs and recent financing.

BiomX Inc. announces the closing of a $12 million offering, including a registered direct offering, a concurrent private placement, and the exercise of existing warrants.

BiomX secures $12 million in funding through a registered direct offering, concurrent private placement, and warrant exercise to support its Phase 2b study of BX004 for cystic fibrosis.

BiomX Inc. announced it has regained compliance with NYSE American listing standards after resolving prior deficiencies.

BiomX reports completion of patient enrollment for its BX211 DFO trial and a delay in the BX004 CF trial results, alongside its Q3 2024 financial results.

BiomX Inc. will mandatorily separate its units into common stock and warrants, with the units ceasing trading on October 25, 2024, while the common stock will continue to trade under the symbol PHGE.

BiomX Inc. presented an investor update on September 26, 2024, detailing progress in their phage therapy programs targeting chronic infections.

BiomX Inc. will implement a 1-for-10 reverse stock split of its common stock and units, effective August 26, 2024.